Aprea Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Aprea Therapeutics, a clinical-stage precision oncology company, reported a net loss of $12.6 million for 2025 and warned of substantial doubt about its ability to continue as a going concern, alongside a Nasdaq minimum bid price deficiency.
NASDAQ
Aprea Therapeutics' 10-K filing reveals significant losses and substantial doubt about its ability to continue as a going concern, despite ongoing Phase 1 clinical trials for its cancer therapeutics APR-1051 and ATRN-119.
NASDAQ
Aprea Therapeutics' 10-K filing details its insider trading policy, outlining restrictions on trading while possessing material nonpublic information and other key guidelines.